"The
Report PharmaPoint: Fibromyalgia - Global Drug Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
The
fibromyalgia market is relatively new and not yet established. Three
drugs currently dominate the sales across the 7MM and form the core
treatment options; Lyrica, Cymbalta and Savella are all approved in
the US while only the former is approved in Japan. Since these drugs
are also available in the 5EU for other indications, they are
prescribed as off-label therapies. A handful of other genericized
products also provide off-label usage including antidepressants,
anti-epileptics, opioids and muscle relaxants. Although Lyrica,
Cymbalta and Savella can provide an effective treatment regimen,
there are ample opportunities for the development of alternative
treatment choices which can expand the medications available to
patients, providing improvement in efficacy, safety and compliance.
By 2023, there will be four new entrants to the market (Lyrica CR,
TNX-102 SL, DS-5565 and TD-9855). These new products will help to
drive market growth and offset some of the patent expiries of the
leading brands during the forecast period. Despite these advancements
in the treatment landscape, fibromyalgia therapeutic sales growth are
expected to be minimal.
View Report At
:http://www.marketresearchreports.biz/analysis/308759
Highlights
Key Questions Answered
-
The fibromyalgia market is marked by the presence of a number of
unmet needs in current treatments. What are the main unmet needs in
this market? Will the drugs under development fulfil the unmet needs
of the fibromyalgia market?
-
The late-stage fibromyalgia pipeline consists of reformulations of
existing therapies, one of which has a novel route of administration,
and me-too products. Which drug will have a significant impact on the
fibromyalgia market? Which of these drugs will have the highest CAGR,
and why?
-
How will the introduction of new therapies change the fibromyalgia
treatment landscape? How will the drug treatment rates change over
the next five years? What are the key drivers and barriers to this
change?
Key Findings
-
The main driver of the expansion of the fibromyalgia market will be
the introduction of four new therapies across the seven major
markets.
-
The biggest barrier for the introduction of new therapies will be
patent expirations of the leading brands marketed for fibromyalgia,
which will result in an increase of generics, and which may
negatively impact revenue from branded drugs that are expected to
launch in the forecast period.
-
The concerns of reducing healthcare costs as part of government
austerity measures, particularly in Europe, which will impede market
growth. To ensure reimbursement companies will have to work closely
together with payers and price their drugs competitively.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/308759
Scope
-
Overview of fibromyalgia, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and treatment guidelines.
-
Annualized fibromyalgia therapeutics market revenue, annual cost of
therapy and treatment usage pattern data from 2013 and forecast for
ten years to 2023.
-
Key topics covered include market characterization, unmet needs, R&D
and clinical trials assessment, late stage clinical trial analysis
and implications for the fibromyalgia therapeutics market.
-
Pipeline analysis: focus on the four late-stage pipeline drugs
discussing emerging trends as well as overview of earlier phase
drugs.
-
Analysis of the current and future market competition in the global
fibromyalgia therapeutics market. Insightful review of the key
industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Reasons to buy
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the global fibromyalgia therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global fibromyalgia therapeutics market in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the global fibromyalgia therapeutics market from
2013-2018.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Table of Contents
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment